Christophe Bourdon, LEO Pharma CEO, on Dermatology Innovation, Rare Disease & Scalable Growth
Synopsis: At a moment when biotech is rethinking growth, innovation, and patient impact, Alok Tayi sits down with Christophe Bourdon, Chief Executive Officer of LEO Pharma, to explore what it truly ...
20 Jan 13min
Matt Gline, Roivant Sciences CEO, on Clinical Breakthroughs, Capital Discipline & Building Biotech
Synopsis: This episode is proudly sponsored by Quartzy. Roivant Sciences CEO Matt Gline returns to Biotech 2050 for a deeply reflective conversation with host Rahul Chaturvedi on what it really tak...
17 Des 202534min
Jay Hartenbach, President & COO, Diakonos Oncology on Reprogramming Cancer Immunity Breakthrough
Synopsis: This episode is proudly sponsored by Quartzy. What happens when engineering discipline, business pragmatism, and breakthrough immunology collide? In this episode of Biotech 2050, host A...
10 Des 202528min
John Lepore, CEO & President - ProFound Therapeutics, on Proteome, AI, & Bold First-in-Class Drugs
Synopsis: This episode is proudly sponsored by Quartzy. In this far-reaching conversation, Rahul Chaturvedi speaks with John Lepore, CEO & President of ProFound Therapeutics and CEO-Partner at Flag...
3 Des 202535min
Jason Kelly - Ginkgo Bioworks CEO and Co-Founder on Automation, AI Data & Biotech’s Reset
Synopsis: This episode is proudly sponsored by Quartzy. Biotech is undergoing a scientific redesign, and Jason Kelly reveals to host Alok Tayi how automation, AI-ready datasets, and modular lab tec...
25 Nov 202539min
Arun Swaminathan: Coya CEO on Neuroinflammation, BD Strategy & Patient-Driven Biotech
Synopsis: In a conversation rich with strategic insight, Coya Therapeutics CEO Arun Swaminathan unpacks the intersections of scientific innovation, business development discipline, and capital-effic...
20 Nov 202537min
How Nimbus CEO Abbas Kazimi Builds Resilient Pipelines Through Culture, Rigor & Smart Bets
Synopsis: Nimbus Therapeutics CEO Abbas Kazimi walks Alok Tayi through the company’s evolving pipeline and playbook for choosing the right risks in a noisy biotech environment. From Werner helicase ...
13 Nov 202542min
Foresite Capital’s Jim Tananbaum on Biotech Cycles, AI Breakthroughs & Long-Term Value
Synopsis: Jim Tananbaum, Founder & CEO of Foresite Capital, joins Rahul Chaturvedi to dissect the patterns driving biotech innovation, the role of macroeconomic cycles in venture performance, and ho...
5 Nov 202523min
